Cormedix Inc Intrinsic Stock Value – CORMEDIX INC Reports Second Quarter Fiscal Year 2023 Earnings Results on June 30th, 2023

August 13, 2023

🌥️Earnings Overview

CORMEDIX INC ($NASDAQ:CRMD) reported its earnings results for the second quarter of fiscal 2023 on June 30, 2023, with total revenue being USD 0.0 million, a decrease of 100.0% from the same period in the prior year. Net income for the quarter saw a decrease to USD -11.3 million, from -7.6 million in the previous year.

Price History

The company’s stock opened at $4.1 per share and closed at $4.4, a 7.9% increase from the previous closing price of $4.1. In addition to the financial figures, CORMEDIX INC also revealed that it has been focused on increasing its global reach and expanding its presence in international markets. The company has launched new products in North America, Europe, and Asia, and is looking to further expand into South America, Australia, and the Middle East. Overall, CORMEDIX INC’s second quarter earnings results show a period of growth and promise for the company.

Investors have responded positively to the news, pushing its stock up by 7.9% in one day. Looking forward, CORMEDIX INC is well-positioned to continue its growth and build on its success in the coming quarters. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Cormedix Inc. More…

    Total Revenues Net Income Net Margin
    0.04 -36.9 -101129.9%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Cormedix Inc. More…

    Operations Investing Financing
    -31.12 -17.19 19.03
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Cormedix Inc. More…

    Total Assets Total Liabilities Book Value Per Share
    57.03 7.98 0.93
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Cormedix Inc are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -40.7% -100964.8%
    FCF Margin ROE ROA
    -85826.2% -44.8% -40.4%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Cormedix Inc Intrinsic Stock Value

    At GoodWhale, we recently conducted an analysis of CORMEDIX INC‘s wellbeing, and the results are quite insightful. According to our proprietary Valuation Line, the fair value of CORMEDIX INC share is around $3.3. However, currently the stock is being traded at $4.4, which means that it is overvalued by 34.5%. Our analysis indicates that there could be some potential opportunities for investors in this company, but they should be careful not to overpay for their shares. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Cormedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat serious cardiometabolic diseases. Cormedix Inc’s lead product candidate, CDX-102, is a first-in-class, orally-available A3 adenosine receptor agonist currently in Phase 2 clinical development for the treatment of heart failure. IVERIC bio Inc is a biopharmaceutical company developing novel treatments for retinal diseases. IVERIC’s most advanced product candidate, Zimura, is a first-in-class, orally-available small molecule that inhibits complement factor C3, a key protein in the complement system that is involved in the development and progression of several retinal diseases. Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on the development of drugs to treat respiratory diseases. Verona Pharma’s lead product candidate, ensifentrine, is a first-in-class inhaled dual inhibitor of the lung inflammation enzymes phosphodiesterase 3 (PDE3) and neutrophil elastase (NE). Gene Biotherapeutics Inc is a biopharmaceutical company developing novel gene therapies for the treatment of rare genetic diseases. Gene Biotherapeutics’ lead product candidate, GBT440, is a first-in-class, adeno-associated virus (AAV) based gene therapy being developed for the treatment of sickle cell disease (SCD).

    – IVERIC bio Inc ($NASDAQ:ISEE)

    Vericel Corporation, a commercial-stage biopharmaceutical company, develops, manufactures, and markets patient-specific expanded cellular therapies to treat severe, debilitating diseases and conditions. The company’s advanced cell therapy product candidates include Carticel and MACI, which are used for the treatment of cartilage defects in the knee; Epicel, an autologous skin substitute that is used for the treatment of patients with deep-dermal or full-thickness burns; and XCART, a CAR-T cell therapy product candidate for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. It also offers ixmyelocel-T, a patient-specific multicellular therapy that is in Phase II clinical trial for the treatment of heart failure. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in July 2015. Vericel Corporation was founded in 1991 and is headquartered in Cambridge, Massachusetts.

    – Verona Pharma PLC ($NASDAQ:VRNA)

    Verona Pharma PLC is a pharmaceutical company that focuses on the development of treatments for respiratory diseases. The company has a market cap of 630.27M as of 2022 and a return on equity of -28.69%. Verona Pharma’s products include RPL554, an inhaled nebulized formulation of the company’s lead drug candidate, and RPL29, a novel inhaled formulation of a corticosteroid. Verona Pharma is headquartered in London, the United Kingdom.

    – Gene Biotherapeutics Inc ($OTCPK:CRXM)

    Gene Biotherapeutics Inc is a clinical stage biopharmaceutical company that focuses on developing and commercializing gene therapies. Its primary focus is on developing its lead product candidate, GBT440, for the treatment of sickle cell disease. The company’s market cap is 6.49k as of 2022 and its ROE is 10.16%.

    The company’s focus on sickle cell disease is significant because there is currently no cure for the disease. Current treatments only address the symptoms of the disease and do not address the underlying cause. This makes GBT440 a potentially groundbreaking treatment for sickle cell disease.

    The company’s market cap and ROE are both solid, indicating that it is a financially sound company. This is important because it indicates that the company has the resources necessary to continue developing GBT440 and bring it to market.


    CORMEDIX INC has reported their earnings for Q2 2023, with total revenue falling 100.0% year-over-year to USD 0.0 million. Net income for the quarter was USD -11.3 million, down from -7.6 million in the prior year. Despite the decrease in revenue and income, the stock price moved up on the same day, indicating that investors are optimistic about the company’s potential.

    This could be due to a number of factors such as new products or services introduced by CORMEDIX INC, potential cost saving measures, or increased strategic focus. Overall, investors should continue to monitor CORMEDIX INC’s financial performance and evaluate any potential catalysts that could affect the stock price in the near future.

    Recent Posts

    Leave a Comment